Effect of conbercept combined with dexamethasone implantation on macular thickness, visual function, retinal perfusion, and inflammatory markers in patients with diabetic macular edema: A prospective controlled study

Conbercept Plus Dexamethasone provides superior long-term structural, functional, and microvascular benefits compared with conventional therapy, likely mediated by enhanced resolution of inflammation. CMT strongly predicts visual outcomes, supporting its use as a primary surrogate marker in clinical management of DME.